医学
肺癌
免疫疗法
肿瘤科
疾病
肺
癌症
内科学
临床试验
作者
Robert Matera,Anne C. Chiang
标识
DOI:10.1016/j.hoc.2023.02.010
摘要
Small cell lung cancer (SCLC) is a rare yet aggressive lung cancer subtype with an extremely poor prognosis of around 1 year. SCLC accounts for 15% of all newly diagnosed lung cancers and is characterized by rapid growth with high potential for metastatic spread and treatment resistance. In the article the authors review some of the most notable efforts to improve outcomes, including trials of novel immunotherapy agents, novel disease targets, and multiple drug combinations.
科研通智能强力驱动
Strongly Powered by AbleSci AI